Abstract
IntroductionBiosimilar Infliximab has been licensed in the UK since 2015 for use in children with Inflammatory Bowel Disease (IBD). The aim is to compare the immunogenicity and response to treatment...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
